Atgam is named as an intervention in 2 current clinical trials in our France and Canada registers. None are recruiting at the moment. The most common phase is Observational. The sponsor with the most trials is European Society for Blood and Marrow Transplantation (1). The most-studied condition is Severe Aplastic Anemia.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
RACE 2: a Long Term Follow-up of Patients Participating in the RACE Trial
NCT05049668 · ClinicalTrials.gov ↗ · Severe Aplastic Anemia
|
Observational | By invitation | European Society for Blood and Marrow Transplantation | France |
|
A Trial Comparing Unrelated Donor BMT With IST for Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202)
NCT05600426 · ClinicalTrials.gov ↗ · Severe Aplastic Anemia
|
Phase 3 | Active, closed | Boston Children's Hospital | Canada |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| European Society for Blood and Marrow Transplantation | 1 |
| Boston Children's Hospital | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in France | 1 | 0 |
| Clinical trials in Canada | 1 | 0 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our France and Canada registers name Atgam as a drug or biological intervention, as of the registry sync on 27 September 2026. Completed and withdrawn studies are not counted.
Not at the moment. None of the 2 trials in our registers is recruiting; they are active but closed to enrolment, not yet open, or enrolling by invitation. Only the study team can confirm whether a patient is eligible.
European Society for Blood and Marrow Transplantation (1) and Boston Children's Hospital (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Atgam works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Atgam works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Atgam (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 27 Sep 2026.